Close Menu

NEW YORK – Sequencing instrument and services firm SeqLL last week halted plans for an $8 million initial public offering.

In an April 24 filing with the US Securities and Exchange Commission, CFO John Kennedy requested withdrawal of SeqLL's Form S-1 registration statement, initially filed April 2019. The firm had planned to offer approximately 1.4 million shares of common stock at an IPO price between $5.40 and $6.40 per share. It would have traded on the Nasdaq under ticker symbol "SQL." WallachBeth Capital was the sole bookrunning manager for the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.